Samlyn Capital LLC Has $156.80 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

Samlyn Capital LLC lessened its position in shares of Natera, Inc. (NASDAQ:NTRA) by 27.0% in the second quarter, HoldingsChannel.com reports. The fund owned 1,447,946 shares of the medical research company’s stock after selling 536,633 shares during the period. Natera comprises approximately 2.6% of Samlyn Capital LLC’s portfolio, making the stock its 8th biggest holding. Samlyn Capital LLC’s holdings in Natera were worth $156,798,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in NTRA. Itau Unibanco Holding S.A. acquired a new stake in Natera in the second quarter worth $28,000. GAMMA Investing LLC lifted its stake in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after buying an additional 108 shares in the last quarter. YHB Investment Advisors Inc. bought a new position in shares of Natera during the first quarter valued at about $36,000. Principal Securities Inc. bought a new position in shares of Natera during the fourth quarter valued at about $32,000. Finally, Tobam bought a new stake in Natera in the second quarter worth about $74,000. Institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other Natera news, CFO Michael Burkes Brophy sold 499 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total transaction of $53,592.60. Following the completion of the sale, the chief financial officer now directly owns 77,418 shares of the company’s stock, valued at approximately $8,314,693.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Michael Burkes Brophy sold 499 shares of the firm’s stock in a transaction on Tuesday, July 23rd. The shares were sold at an average price of $107.40, for a total value of $53,592.60. Following the completion of the transaction, the chief financial officer now directly owns 77,418 shares of the company’s stock, valued at $8,314,693.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jonathan Sheena sold 2,700 shares of the firm’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $127.57, for a total transaction of $344,439.00. Following the completion of the transaction, the insider now directly owns 284,741 shares of the company’s stock, valued at $36,324,409.37. The disclosure for this sale can be found here. Insiders sold a total of 93,921 shares of company stock valued at $10,551,281 in the last three months. 7.60% of the stock is currently owned by corporate insiders.

Natera Trading Down 3.3 %

Shares of NTRA opened at $123.54 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $132.01. The company has a 50 day simple moving average of $114.66 and a two-hundred day simple moving average of $105.76. The firm has a market cap of $15.17 billion, a P/E ratio of -39.60 and a beta of 1.53.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The business had revenue of $413.35 million during the quarter, compared to analyst estimates of $343.00 million. During the same period last year, the firm posted ($0.97) EPS. The company’s revenue was up 58.1% on a year-over-year basis. On average, equities analysts expect that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Piper Sandler reaffirmed an “overweight” rating and set a $150.00 price objective on shares of Natera in a research note on Friday, September 13th. UBS Group dropped their target price on shares of Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Wednesday, August 28th. BTIG Research upped their price target on shares of Natera from $125.00 to $135.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Robert W. Baird boosted their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $120.07.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.